Literature DB >> 18034620

677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.

Mateusz Kurzawski1, Andrzej Pawlik, Krzysztof Safranow, Magdalena Herczynska, Marek Drozdzik.   

Abstract

INTRODUCTION: Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity.
METHODS: To examine the association between 677C>T and 1298A>C MTHFR polymorphisms and MTX efficacy in the treatment of RA, a total of 174 RA patients, treated with MTX plus methylprednisone 4 mg and folic acid 5 mg were analyzed.
RESULTS: In univariate regression analysis model, the MTHFR 677T allele was associated with significantly higher frequency of remission, whereas in the case of the 1298C allele, a tendency for higher remission rate was observed. In multivariate regression analysis, the presence of both 677T and 1298C alleles was associated with an increased frequency of remission.
CONCLUSION: The results of our study suggest that the MTHFR 677T and 1298C alleles may be associated with an increased rate of RA remission in patients treated with MTX receiving high doses of folic acid supplementation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034620     DOI: 10.2217/14622416.8.11.1551

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  19 in total

Review 1.  Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Authors:  Heinrike Schmeling; Gerd Horneff; Susanne M Benseler; Marvin J Fritzler
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

2.  Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.

Authors:  Paula I Burgos; Maria I Danila; James M Kelley; Laura B Hughes; S Louis Bridges
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

3.  Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.

Authors:  Souhir Chaabane; Sameh Marzouk; Rim Akrout; Mariem Ben Hamad; Yosser Achour; Ahmed Rebai; Leila Keskes; Hela Fourati; Zouhir Bahloul; Abdellatif Maalej
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

4.  Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.

Authors:  Galina Kislukhin; Maura L Murphy; Mahtab Jafari; Anthony D Long
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

Review 5.  Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritis.

Authors:  Robert M Plenge; Soumya Raychaudhuri
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

6.  Higher serum folate levels are associated with a lower risk of atopy and wheeze.

Authors:  Elizabeth C Matsui; William Matsui
Journal:  J Allergy Clin Immunol       Date:  2009-05-05       Impact factor: 10.793

7.  Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.

Authors:  Mark C Fisher; Bruce N Cronstein
Journal:  J Rheumatol       Date:  2009-02-04       Impact factor: 4.666

8.  Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.

Authors:  Petra Bohanec Grabar; Dusan Logar; Boris Lestan; Vita Dolzan
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

Review 9.  Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Gwan Gyu Song
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

10.  Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.

Authors:  Yvonne C Lee; Jing Cui; Karen H Costenbader; Nancy A Shadick; Michael E Weinblatt; Elizabeth W Karlson
Journal:  Rheumatology (Oxford)       Date:  2009-02-04       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.